Newsq

Vaccine controls HIV infection
Enlarge image

ResearchSpainFrance

Vaccine controls HIV infection

03.01.2013 - Spanish and French researchers have found a therapeutic vaccine strategy to boost the immune response to HIV.

A therapeutic vaccine that uses heat-inactivated HIV appears to boost the immune response to the virus in people, reports Science Translational Medicine. The findings pave the way for the development of vaccines that could potentially control HIV replication without the need for life-long antiretroviral medication. The vaccine is made from treated dendritic cells or DCs.

When a microorganism like HIV invades the body, cells called phagocytes chop up the virus and break it into small fragments. Some of these pieces find their way into the membranes of DCs. The DCs then present the pieces of HIV to lymphocytes, white blood cells that then launch a specific immune response against the virus. The problem is that DCs can also carry a part of the infectious virus on their outer membrane. Consequently, the white blood cells can get infected and die instead of developing an immune response.

To avoid this problem, Felipe García from University of Barcelona and colleagues from CRNS Paris primed the DCs of 36 patients with heat-inactivated HIV and then delivered the DCs back into patients as a therapeutic vaccine. The exposure to inactivated HIV allows the DCs to deliver their message to the white blood cells without harming them. The researchers found that vaccine was able to stimulate a noticeable degree of immune response against HIV, and that higher responses correlated with better control of virus replication. However, it is not yet clear how much of an immune response is needed to make an effective vaccine. Importantly, the vaccine appeared to be safe and well-tolerated. The results offer evidence that future HIV vaccines could help control the virus.

Earlier in December another research team from Barcelona had presented a different strategy to prevent HIV infection of human CD4 lymphocytes. By blocking HIV entry into DCs they were able to prevent CD4 cells from viral invasion.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/vaccine-controls-hiv-infection.html

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

BusinessSweden

10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.

M&AIreland

08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.

BusinessIreland

07.07.2015 Irish pharma play Allergan plc. is boosting its eye care business by acquiring US-American medtech company Oculeve. Included in the deal are Oculeve’s dry eye disease development programmes.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • KAROLINSKA (S)12.95 SEK8.37%
  • IXICO (UK)35.50 GBP5.97%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • MEDIGENE (D)9.65 EUR-10.32%
  • SERODUS (N)3.08 NOK-8.88%
  • ZELTIA (E)3.69 EUR-8.44%

TOP

  • IXICO (UK)35.50 GBP57.8%
  • DBV TECHNOLOGIES (F)75.75 EUR43.9%
  • ADOCIA (F)88.67 EUR28.9%

FLOP

  • BIOTEST (D)25.26 EUR-64.3%
  • BIOTECH PHARMACON (N)9.44 NOK-47.6%
  • TRANSGENE (F)2.95 EUR-39.4%

TOP

  • ADOCIA (F)88.67 EUR532.9%
  • VERONA PHARMA (UK)4.88 GBP324.3%
  • FORMYCON (D)28.20 EUR305.8%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • NEOVACS (F)1.05 EUR-69.6%
  • BIOTEST (D)25.26 EUR-69.3%

No liability assumed, Date: 27.07.2015